Total Payments
$3,694
2024 Payments
$963.48
Companies
26
Transactions
193
Medicare Patients
2,755
Medicare Billing
$198,828
Payment Breakdown by Category
Food & Beverage$3,562 (96.4%)
Education$131.99 (3.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,562 | 191 | 96.4% |
| Education | $131.99 | 2 | 3.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $443.45 | 22 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $442.93 | 44 | $0 (2024) |
| Janssen Biotech, Inc. | $392.62 | 26 | $0 (2024) |
| GENZYME CORPORATION | $341.50 | 12 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $280.80 | 4 | $0 (2024) |
| UCB, Inc. | $278.44 | 13 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $231.82 | 2 | $0 (2019) |
| Lilly USA, LLC | $218.80 | 12 | $0 (2023) |
| PFIZER INC. | $189.06 | 11 | $0 (2024) |
| Dermavant Sciences, Inc. | $113.16 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $963.48 | 60 | UCB, Inc. ($184.45) |
| 2023 | $625.97 | 30 | Janssen Biotech, Inc. ($130.54) |
| 2022 | $556.23 | 28 | ABBVIE INC. ($143.61) |
| 2021 | $67.19 | 4 | GENZYME CORPORATION ($24.65) |
| 2020 | $58.54 | 3 | LEO Pharma Inc. ($22.95) |
| 2019 | $652.16 | 31 | Regeneron Healthcare Solutions, Inc. ($130.40) |
| 2018 | $429.08 | 19 | Regeneron Healthcare Solutions, Inc. ($111.36) |
| 2017 | $341.67 | 18 | Janssen Scientific Affairs, LLC ($106.82) |
All Payment Transactions
193 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $26.92 | General |
| Category: Inflammation | ||||||
| 12/16/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $11.93 | General |
| Category: Immunology | ||||||
| 12/16/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $4.01 | General |
| Category: Immunology | ||||||
| 12/13/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $12.35 | General |
| Category: Dermatology | ||||||
| 11/22/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $12.53 | General |
| Category: Dermatology | ||||||
| 11/13/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $2.74 | General |
| Category: Dermatology | ||||||
| 11/04/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $43.90 | General |
| Category: Immunology | ||||||
| 10/28/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $16.26 | General |
| 10/25/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $14.13 | General |
| Category: Dermatology | ||||||
| 10/09/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $1.92 | General |
| Category: Dermatology | ||||||
| 10/09/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $0.27 | General |
| Category: Dermatology | ||||||
| 09/30/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $33.55 | General |
| Category: Immunology | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $11.34 | General |
| Category: Dermatology | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $0.41 | General |
| Category: Dermatology | ||||||
| 09/26/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $19.76 | General |
| Category: DERMATOLOGY | ||||||
| 09/10/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $5.97 | General |
| Category: Dermatology | ||||||
| 09/09/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: IMMUNOLOGY | ||||||
| 08/28/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $24.56 | General |
| Category: Immunology | ||||||
| 08/12/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $35.77 | General |
| Category: Immunology | ||||||
| 08/05/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $5.83 | General |
| Category: Immunology | ||||||
| 07/29/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $26.37 | General |
| Category: Immunology | ||||||
| 07/26/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $12.69 | General |
| Category: Dermatology | ||||||
| 07/26/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $0.21 | General |
| Category: Dermatology | ||||||
| 07/15/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $28.77 | General |
| Category: Immunology | ||||||
| 07/15/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $24.28 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 702 | 1,197 | $121,313 | $51,372 |
| 2022 | 9 | 644 | 1,179 | $110,801 | $48,192 |
| 2021 | 10 | 735 | 1,364 | $132,329 | $58,763 |
| 2020 | 9 | 674 | 1,102 | $104,891 | $40,501 |
Total Patients
2,755
Total Services
4,842
Medicare Billing
$198,828
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 203 | 269 | $35,360 | $16,151 | 45.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 125 | 167 | $32,064 | $14,780 | 46.1% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 131 | 162 | $18,144 | $6,052 | 33.4% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 69 | 78 | $14,742 | $6,023 | 40.9% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 51 | 57 | $9,519 | $3,517 | 36.9% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 83 | 421 | $3,789 | $1,828 | 48.3% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 14 | 15 | $3,660 | $1,449 | 39.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 15 | 15 | $2,865 | $1,073 | 37.4% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 11 | 13 | $1,170 | $499.96 | 42.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 187 | 236 | $30,680 | $14,678 | 47.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 104 | 137 | $26,304 | $11,876 | 45.1% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 112 | 151 | $16,912 | $5,726 | 33.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 55 | 61 | $11,529 | $4,941 | 42.9% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 52 | 62 | $10,354 | $4,311 | 41.6% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 81 | 468 | $4,212 | $2,202 | 52.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 15 | 15 | $4,380 | $1,856 | 42.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 20 | 20 | $3,820 | $1,449 | 37.9% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 18 | 29 | $2,610 | $1,153 | 44.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 186 | 247 | $32,110 | $15,781 | 49.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 122 | 165 | $31,680 | $15,008 | 47.4% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 66 | 77 | $14,553 | $6,396 | 44.0% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 73 | 89 | $14,863 | $6,098 | 41.0% |
| 17000 | Destruction of skin growth | Office | 2021 | 110 | 144 | $16,128 | $5,425 | 33.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 23 | 23 | $6,716 | $2,658 | 39.6% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 31 | 31 | $6,091 | $2,396 | 39.3% |
About Dr. Michael Bobrow, MD
Dr. Michael Bobrow, MD is a Pediatric Dermatology healthcare provider based in Rochester, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1467416768.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Bobrow, MD has received a total of $3,694 in payments from pharmaceutical and medical device companies, with $963.48 received in 2024. These payments were reported across 193 transactions from 26 companies. The most common payment nature is "Food and Beverage" ($3,562).
As a Medicare-enrolled provider, Bobrow has provided services to 2,755 Medicare beneficiaries, totaling 4,842 services with total Medicare billing of $198,828. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Pediatric Dermatology
- Other Specialties Procedural Dermatology, Dermatology
- Location Rochester, NY
- Active Since 04/13/2006
- Last Updated 11/10/2023
- Taxonomy Code 207NP0225X
- Entity Type Individual
- NPI Number 1467416768
Products in Payments
- DUPIXENT (Biological) $434.62
- TREMFYA (Drug) $273.91
- TALTZ (Drug) $218.80
- Bimzelx (Biological) $207.70
- COSENTYX (Biological) $198.19
- COSENTYX (Drug) $183.18
- RINVOQ (Biological) $166.24
- Humira (Biological) $161.14
- EUCRISA (Drug) $143.82
- Tremfya (Drug) $125.00
- REMICADE (Biological) $118.71
- LIBTAYO (Biological) $114.44
- VTAMA (Drug) $113.16
- DUPIXENT DUPILUMAB INJECTION (Biological) $111.36
- STELARA (Biological) $106.82
- Otezla (Drug) $99.26
- Sotyktu (Drug) $97.26
- SKYRIZI (Biological) $90.71
- Cimzia (Drug) $70.74
- ENSTILAR (Drug) $50.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.